Pharmacological properties of the human P2Y 1 receptor transfected in Jurkat cells and of the endogenous receptor in rat brain capillary endothelial cells were analyzed under conditions in which the purity of adenine triphosphate nucleotides was controlled by creatine phosphate/creatine phosphokinase (CP/ CPK). ATP, a partial agonist of the receptor, was inactive in the presence of CP/CPK. Results further indicated that ATP was a competitive antagonist of ADP actions. In conclusion, the rat and human P2Y 1 receptors are ADPspecific receptors that recognize ADP and 2-methylthio-ADP, whereas ATP, 2-MeSATP, and 2-ClATP are competitive antagonists. The results further point to the close pharmacological similarity of the P2Y 1 receptor and the platelet ADP receptor.
2-ClATP antagonized platelet aggregation induced by ADP. They did not activate P2Y 1 receptors but prevented ADP actions in a competitive manner. K i values for 2-MeSATP were 36.5 M in endothelial cells and 5.7 Ϯ 0.4 M in Jurkat cells, and K i values for 2-ClATP were 27.5 M in endothelial cells and 2.3 Ϯ 0.3 M in Jurkat cells. EDTA potentiated actions of ADP and ATP on endothelial cells by 2.4-and 3.6-fold, respectively. In conclusion, the rat and human P2Y 1 receptors are ADPspecific receptors that recognize ADP and 2-methylthio-ADP, whereas ATP, 2-MeSATP, and 2-ClATP are competitive antagonists. The results further point to the close pharmacological similarity of the P2Y 1 receptor and the platelet ADP receptor.
Purinergic responses of the P2 type are mediated by two classes of membrane receptor: ionotropic P2X receptors and metabotropic P2Y receptors (Abbracchio and Burnstock, 1994; Harden et al., 1995; Burnstock and King, 1996; Weissman et al., 1996) . The structures of P2Y 1 receptors from chicken (Webb et al., 1993) , turkey (Filtz et al., 1994) , bovine (Henderson et al., 1995) , rat, mouse (Tokuyama et al., 1995) , and human (Ayyanathan et al., 1996; Léon et al., 1996) species are known. ATP, 2-MeSATP, 2-ClATP, 2-MeSADP, and ADP usually are considered to be potent agonists of P2Y 1 receptors (Boyer et al., 1993; Vigne et al., 1994; Boyer et al., 1996; Schachter et al., 1996) , although ATP has been reported in some studies to be only a partial agonist (Feolde et al., 1995; Henderson et al., 1995; Léon et al., 1997) . Characterization of the pharmacological properties of purinoceptors is, however, difficult because nucleotides from commercial sources do not have the desired purity and the purity of their aqueous solutions decreases considerably during storage. In addition, nucleotides can be degraded by cellular ectonucleotidases. These difficulties can be circumvented by using freshly purified nucleotides or enzymatic systems that regenerate degraded nucleotides . In a previous article, we described the pharmacological characteristics of the human P2Y 1 receptor transfected into Jurkat cells. Results showed that (1) ADP was a selective agonist of this receptor, (2) freshly purified ATP and ATP derivatives were ineffective, and (3) ATP antagonized the effects of ADP . On the other hand, purified 2-MeSATP and 2-ClATP were found to be full agonists but with delayed responses compared with the corresponding diphosphate derivatives. It was suggested that the triphosphate analogues were metabolized into diphosphates by ectoenzymes, thus explaining their apparent agonistic effect. These results led us to put forward the idea that the P2Y 1 receptor is similar to the platelet ADP receptor, the elusive P2T receptor .
The first aim of the current study was to determine the conditions that allow control of the purity of ATP nucleotides by means of a CP/CPK ATP-regenerating system. This tech-nique then was used to define more precisely the pharmacological properties of the human P2Y 1 receptor expressed in Jurkat cells and the endogenous P2Y 1 receptor expressed in rat brain capillary endothelial cells . These latter cells were found previously to express specific ADP receptors at which ATP behaved as a partial agonist (Frelin et al., 1993; Feolde et al., 1995) . Results showed the rat and human P2Y 1 receptors to be ADP-specific receptors antagonized by ATP and its derivatives, 2-ClATP and 2-MeSATP, thus pointing to the existence of strong pharmacological similarities between the endothelial P2Y 1 receptor and the platelet ADP receptor.
Experimental Procedures
Materials. ATP, ADP, iodoacetamide, creatine, CP, and CPK (Type III from bovine heart) were from Sigma Chemical (St. QuentinFallavier, France). Indo-1/AM was from Calbiochem (Meudon, France), whereas 2-ClATP, 2-MeSADP, and 2-MeSATP were from Research Biochemicals (Natick, MA).
Cell cultures and intracellular Ca 2؉ measurements. Rat brain capillary endothelial cells of the B10 clone (Feolde et al., 1995) and Jurkat cells stably transfected with the human P2Y 1 receptor have been described previously. The human P2Y 1 receptor sequence differs from that originally described (Léon et al., 1996) by the presence of an additional 3 base pairs leading to an additional serine residue in transmembrane domain 3, between residues 137 and 138 ). An identical sequence was reported by . B10 cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum, 100 units/ml penicillin, and 0.1 mg/ml streptomycin. Jurkat cells were grown in RPMI-1640 medium supplemented with 10% heat-inactivated fetal calf serum, 2 mM glutamine, 100 units/ml penicillin, 0.1 mg/ml streptomycin, and 1 mg/ml geneticin. Suspensions of Jurkat cells and B10 cells were incubated for 30 min in the presence of 5 M indo-1/AM. The cells then were diluted in Earle's salt solution (140 mM NaCl, 5 mM KCl, 1.8 mM CaCl 2 , 0.8 mM MgCl 2 , 5 mM glucose, 25 mM HEPES/NaOH, pH 7.4) and exposed to nucleotides, and the indo-1 fluorescence ratio was measured by flow cytometry using a FACStar Plus cytometer (Becton Dickinson, Le Pont de Claix, France) (Vigne et al., 1994) . Mean fluorescence ratios were determined for 5000 Jurkat cells or 1000 B10 cells sampled 15 sec after the addition of agonists and all experiments were performed at 37°. The acquisition time was 2 sec. Fluorescence ratios were calculated in arbitrary units set to a value of 100 for unstimulated cells. Triplicate determinations were performed. Each experiment was repeated at least three times. Error bars omitted on the figures were smaller than the size of the points. All experiments shown in a given figure were performed on the same batch of cells.
Purification of ATP and ATP derivative solutions. The purity of nucleotide solutions was checked by HPLC analysis ) on a Partisil 10-m SAX column (Interchrom; Interchim, Montluçon, France) eluted with a linear gradient from 0% to 100% of 1 M ammonium phosphate buffer, pH 3.8, after 20 min with a flow rate of 1 ml/min. Absorbance was recorded at 260 nm for ATP and 274 nm for 2-ClATP and 2-MeSATP. As discussed previously Léon et al., 1997) , commercial nucleotide powders often are contaminated by degradation products that can be the cause of misleading results. Contamination was usually 1% for ATP and Ϸ10% for 2-MeSATP and 2-ClATP (see Results). Nucleotides also may be degraded by cell ectonucleotidases. Problems arising from the contamination and degradation of ATP solutions were circumvented by using an ATP-regenerating system. ATP solutions (1 mM) were treated at room temperature with 20 units/ml CPK and 10 mM CP, and the entire mixture was added to cell suspensions. The same procedure was used to purify 2-ClATP and 2-MeSATP solutions from contaminating ADP derivatives. Time course experiments indicated, however, that exposition to CPK had to be increased to remove contaminants of 2-MeSATP and 2-ClATP solutions. A 30-min incubation period was necessary to purify 2-ClATP solutions. This time was 90 min for 2-MeSATP. These differences probably reflect different catalytic efficiencies of CPK toward ATP, 2-ClATP, and 2-MeSATP. Contaminant 2-MeSADP and 2-ClADP were identified by mass spectrometry using a Bio-Q triple quadrupole mass spectrometer (Micromass Ltd, Altrincham, UK).
In assays to determine the antagonistic action of ATP derivatives, CPK was inactivated with 10 mM iodoacetamide before the experiments.
Platelet aggregation. Aggregation was measured at 37°by a turbidimetric method in a dual-channel Payton aggregometer (Payton Associates, Scarborough, Ontario, Canada). A 450-l aliquot of citrated platelet-rich plasma was stirred at 1100 rpm and activated by the addition of agonists to a final volume of 500 l (Cazenave et al., 1983) .
Curves were fitted with a logistic equation using SigmaPlot software (Jandel Scientific, Costa Madre, CA). Mean Ϯ standard error values are indicated.
Results
Partial agonism of ATP is abolished in the presence of an ATP-regenerating system. Purinergic responses were analyzed in rat brain capillary endothelial cells of the B10 clone that specifically express mRNA sequences corresponding to the cloned P2Y 1 receptor and on P2Y 1 receptor-transfected Jurkat cells. Fig. 1 further shows that as reported previously (Feolde et al., 1995; Léon et al., 1997) , ATP was a partial agonist compared with ADP in the two cell types. EC 50 values for the actions of ATP were 22 Ϯ 6 M (10 experiments) in B10 cells and 11 Ϯ 7 M (3 experiments) in Jurkat cells. We noticed, however, that the maximum efficacy of ATP varied among experiments, even within the same day. This led us to postulate that actions of ATP were mediated by a contaminant that spontaneously arose during storage of the solutions. Purity of ATP solutions was assessed by HPLC. Experiments indicated that freshly prepared ATP solutions were contaminated by Ϸ1% ADP and that contamination of ATP solutions by ADP increased rapidly on storage of the solutions. It may reach several percentage points after a few hours. ADP also may be generated from ATP by cell ectonucleotidases. One way of avoiding spontaneous or cell-mediated degradation of ATP into ADP and to control ATP concentrations is to use an ATP-regenerating system. In the presence of CP, CPK transforms ADP into ATP and thus counteracts any degradation of ATP into ADP. Fig. 1 shows the results of experiments performed in the presence of CP and CPK. It shows that under such conditions, ATP did not raise [Ca 2ϩ ] i in either Jurkat or B10 cells. CP or CPK alone did not inhibit ATP responses. Fig. 1B further shows that a mixture of creatine and CPK that transformed ATP into ADP did not inhibit ADP action. Taken together, these results indicated that ATP was inactive on B10 or Jurkat cells. The actions of ATP that were observed in the absence of ATP-regenerating system were likely mediated by contaminating ADP; contamination resulted from the spontaneous degradation of ATP or from ATP hydrolysis by cellular ectonucleotidases.
ATP inhibits ADP-induced intracellular Ca 2؉ mobilization. In B10 cells, ATP (0.1 mM) inhibited the action of ADP by shifting the dose-response curve to higher concentrations ( Fig. 2A) . ATP did not, however, modify the maximum efficacy of ADP. EC 50 values for ADP were 0.88 Ϯ 0.12, 6.4 Ϯ 0.5, and 49 Ϯ 9 M in the presence of no ATP, 100 M ATP, and 1 mM ATP, respectively. The K i value for ATP Fig. 2A (inset) shows the dose-response curve for the inhibition by ATP of responses induced in B10 cells by 300 nM ADP. In seven independent experiments, the K i value for ATP was estimated to be 23.8 Ϯ 3.3 M. The mean K i value for ATP estimated from these three types of experiments was 23.0 Ϯ 1.5 M.
Similar experiments were performed on P2Y 1 receptortransfected Jurkat cells (Fig. 2B) . ATP (0.1 mM) shifted the dose-response curve of ADP to higher concentrations without affecting its maximum efficacy. A plot of EC 50 values for ADP as a function of ATP concentration (Fig. 2B, inset) mobilization. Fig. 3 (inset) shows the HPLC profile of a freshly prepared 2-MeSATP solution that contained Ͼ10% of a major contaminant (peak 1). This contaminant had the same retention time as 2-MeSADP. It induced platelet aggregation and was identified as 2-MeSADP by mass spectrometry analysis. Fig. 3 further shows that a 90-min treatment of a 2-MeSATP solution with 20 units/ml CPK and 10 mM CP almost completely removed contaminating 2-MeSADP from the solution. The biological activity of purified 2-MeSATP was checked in a platelet aggregation assay. It is well known that although 2-MeSADP is a potent agonist of platelet aggregation, 2-MeSATP is an antagonist (Hall and Hourani, 1993) . In Fig. 3 , it can be seen that purification of 2-MeSATP solutions with CP/CPK suppressed the aggregative effect of 2-MeSATP (traces a and b, left) and further that as expected 50 M purified 2-MeSATP abolished the action of 5 M ADP (traces a and b, right). Fig. 4 shows that as reported previously (Feolde et al., 1995; Léon et al., 1997) , unpurified 2-MeSATP was a potent agonist of P2Y 1 receptors in Jurkat and B10 cells. EC 50 values for the actions of 2-MeSATP were 310 Ϯ 60 nM (five experiments) in B10 cells and 45 Ϯ 13 nM (three experiments) in Jurkat cells. Fig. 4 further shows that a treatment of 2-MeSATP solutions with CP and CPK almost completely abolished its agonist action.
In B10 cells, purified 2-MeSATP (100 M) competitively inhibited the action of ADP without affecting its maximum efficacy (Fig. 5A) . The EC 50 value for ADP was 0.91 Ϯ 0.06 M in the absence of 2-MeSATP and 3.3 Ϯ 0.5 M in the presence of 100 M 2-MeSATP. The 3.6-fold shift gave an estimated K i value of 38 M. 2-MeSATP also inhibited responses induced by 1 M ADP (Fig. 5A, inset) . The concentration of 2-MeSATP producing half-maximal inhibition of the ADP signal (IC 50 ) was 77 Ϯ 13 M, which corresponded to a K i value of 35 M. The mean K i value for 2-MeSATP estimated from these two types of experiments was 36.5 M.
Similarly, 2-MeSATP (100 M) antagonized ADP responses in P2Y 1 receptor-transfected Jurkat cells (Fig. 5B) . A plot of EC 50 values for ADP as a function of 2-MeSATP concentration was linear (Fig. 5B, inset) , and the slope indicated a K i mobilization. Fig. 6 (left, inset) shows the HPLC profile of a freshly prepared 2-ClATP solution that contained Ͼ10% of a major contaminant (peak 1). This contaminant induced platelet aggregation and was identified as 2-ClADP in mass spectrometry experiments. It was completely removed by 30-min treatment of the solution with 20 units/ml CPK and 10 mM CP (Fig. 6, inset) . Purified 2-ClATP did not induce platelet aggregation (Fig. 6, left) and inhibited the action of ADP (Fig.  6 , right), in accordance with the known antagonism of platelet ADP receptors by 2-ClATP (Hall and Hourani, 1993) . Fig. 7 shows that as reported previously (Feolde et al., 1995; Léon et al., 1997) , unpurified 2-ClATP is a potent agonist of P2Y 1 receptors in Jurkat and B10 cells. EC 50 values for the actions of 2-ClATP were 200 Ϯ 37 nM (four experiments) in B10 cells and 40 Ϯ 4 nM nM (three experiments) in Jurkat cells. Fig. 7 further shows that a treatment of 2-ClATP solutions with CP and CPK almost completely abolished its agonist action.
In B10 cells, purified 2-ClATP (100 M) increased the EC 50 value for the action of ADP on [Ca 2ϩ ] i from 0.98 Ϯ 0.09 to 3.7 Ϯ 0.8 M without modifying its maximum efficacy (Fig.  8A) . This 3.8-fold shift indicated a K i value of 36 M. 2-ClATP further inhibited responses to 1 M ADP (Fig. 8A, inset) , with an IC 50 value of 41 Ϯ 5 M corresponding to a K i value of 19 M. The mean K i value for 2-ClATP estimated from these two types of experiments was 27.5 M.
2-ClATP antagonized ADP responses in P2Y 1 receptortransfected Jurkat cells in a similar manner (Fig. 8B) . A plot of EC 50 values for ADP as a function of 2-ClATP concentration was linear (Fig. 8B, inset) and gave a slope indicating a K i value of 2.5 M. 2-ClATP also shifted the dose-response curve for the action of 2-MeSADP on [Ca 2ϩ ] i . EC 50 values for 2-MeSADP were 3.6 Ϯ 1.3 nM in the absence of 2-ClATP and 213 Ϯ 46 nM in the presence of 100 M 2-ClATP (data not shown), which corresponded to a K i value of 1.7 M. Last, 2-ClATP inhibited responses to 300 nM ADP with an estimated K i value of 2.7 M (data not shown). The mean K i value for 2-ClATP estimated from these three types of experiments was 2.3 Ϯ 0.3 M.
Thus, 2-ClATP behaved as a competitive antagonist of the P2Y 1 receptors in B10 and Jurkat cells, with inhibition constants of 27 and 2.3 M, respectively.
EDTA potentiates the effects of ADP and ATP. In physiological buffers, ATP and ADP exist as mixtures of several species, including forms that are complexed with monovalent and divalent cations and free ADP 3Ϫ and ATP
4Ϫ
forms. The species constituting the preferential ligand of a receptor can be determined by investigating the effects of divalent cations on the action of ADP or ATP. Fig. 9A compares dose-response curves for the action of ADP on [Ca 2ϩ ] i in B10 cells in experiments performed in the presence or absence of 5 mM EDTA. The addition of EDTA decreased the EC 50 value for ADP action from 0.86 Ϯ 0.08 M (7 experiments) to 0.35 Ϯ 0.03 M (4 experiments). Thus, chelation of extracellular divalent cations with EDTA increased by 2.4-fold the potency of ADP. EDTA also potentiated the inhibitory action of ATP on ADP-induced [Ca 2ϩ ] i increase in B10 cells (Fig. 9B) . The mean K i value for ATP action decreased from 23.8 Ϯ 3.3 M (7 experiments) in the absence of EDTA to 6.5 Ϯ 1.3 M (13 experiments) in the presence of 5 mM EDTA. These values were calculated by using EC 50 values for 
Discussion
ATP, 2-ClATP, and 2-MeSATP usually are considered to be agonists of P2Y 1 receptors (Boyer et al., 1993; Vigne et al., 1994; Boyer et al., 1996; Burnstock and King, 1996; Schachter et al., 1996) . In the current study, the pharmacological properties of rat and human P2Y 1 receptors were studied under conditions in which care was taken to purify the agonist solutions of contaminating ADP or ADP derivatives by treatment with CP/CPK. The agonistic action of ATP, 2-MeSATP, and 2-ClATP was suppressed in the presence of this ATP-regenerating system. Any possibility that CP/CPK inhibited purinergic responses through a nonspecific mechanism was ruled out by the following observations: (1) CPK or CP alone was inactive, (2) creatine/CPK did not modify ADP responses, and (3) iodoacetamide-inactivated CPK and CP did not alter ADP responses. These findings suggested that the previously reported agonistic effects of ATP and its derivatives were most likely due to contaminating ADP or ADP derivatives, present in the unpurified agonist solutions or produced at the cell surface by ectoenzymes, or both. Thus, the human P2Y 1 receptor expressed in Jurkat cells and the endogenous P2Y 1 receptor of B10 cells appear to be ADP-specific receptors. This, together with a previous report , points to a remarkable specificity of P2Y receptors. Mammalian P2Y receptors can be classified as an ADP-specific receptor (P2Y 1 receptor), a UDP-specific receptor (P2Y 6 receptor), a UTP-selective receptor (P2Y 4 receptor), or a mixed ATP/UTP receptor (P2Y 2 receptor) .
This study also showed that purified solutions of ATP, 2-ClATP, or 2-MeSATP shifted ADP dose-response curves to higher concentrations in both B10 cells and P2Y Different results were reported by Schachter et al.(1996) , who reported full agonistic activity of 2-MeSADP, 2-Me-SATP, ADP, and ATP. This pharmacological profile resulted from measurement of inositol phosphate production after 10-min incubation of the human P2Y 1 receptor-transfected 1321N1 cells with nonpurified nucleotides. These experimental conditions, under which metabolic transformation of the nucle- In their study, [Ca 2ϩ ] i increase was measured on few cells adhering to a coverslip perfused with HPLC-purified nucleotides but in the absence of an ATP-regenerating system. These new data are fully consistent with the results presented in the current report.
The potencies of ADP and ATP at the rat P2Y 1 receptor were increased 2.4-and 3.6-fold, respectively, when extracellular divalent cations were chelated with EDTA (Fig. 6 ). This could imply that the P2Y 1 receptor is more responsive to charged forms of nucleotides than to forms that are complexed with divalent cations. However, the situation probably is not so simple because a larger shift in affinity for ATP would be expected if only ATP 4Ϫ were acting on receptors; although ATP 4Ϫ is the preferred ligand of the P2Y 1 receptor, it also may be recognized by other forms of ATP.
Despite spectacular advances in recent years in the fields of ionotropic P2X and metabotropic P2Y receptors, the putative platelet-specific ADP receptor (P2T), which was the first purinoceptor to be defined pharmacologically, has not yet been cloned (Hourani and Hall, 1996; Mills, 1996; . In a previous publication, we suggested that the P2Y 1 receptor could be this elusive ADP receptor of platelets . The results presented here provide further evidence of close similarities in the pharmacological profiles of the P2Y 1 receptor and the platelet ADP receptor.
First, ATP, 2-ClATP, and 2-MeSATP are antagonists of the ADP receptor of platelets (Hall and Hourani, 1993) and of the rat and human P2Y 1 receptors. The K i value of ATP for the human P2Y 1 receptor in Jurkat cells (16 M) is similar to that reported for the ADP receptor of platelets (10 M) (Hall and Hourani, 1993) . The K i value of 2-ClATP in Jurkat cells (2.3 M) likewise is close to that reported for the platelet ADP receptor (2.5 M) (Hall and Hourani, 1993) . The only difference between the human P2Y 1 receptor in Jurkat cells and the platelet ADP receptor relates to 2-MeSATP. 2-MeSATP is a competitive antagonist of ADP actions in Jurkat cells (Fig.  4B) , whereas it was found to be an insurmountable antagonist of ADP actions in platelets (Hall and Hourani, 1993) .
Second, ADP 3Ϫ is a 2.4 times more potent activator of the rat P2Y 1 receptor than ADP (Fig. 6A) and a 1.9 times more potent activator of the ADP receptor of platelets (Hall et al., 1994) . Conversely, chelation of divalent cations with EDTA increased by 3.6-fold the capacity of ATP to inhibit the rat P2Y 1 receptor, whereas the ability of ATP to inhibit the platelet ADP receptor increased Ϸ10-fold when experiments were performed in the absence of divalent cations (Hall et al., 1994) .
On the other hand, the only form of P2Y receptor detected to date in platelets is the P2Y 1 receptor , as also is true in B10 cells . Another striking similarity is the fact that although ADP induces the mobilization of intracellular Ca 2ϩ stores in platelets and B10 cells, in both cases inositol-1,4,5-trisphosphate seems to be only poorly involved in this response (Feolde et al., 1995; Hourani and Hall, 1996; Mills, 1996; Gachet et al., 1997) .
In summary, our results and data from the literature strongly suggest that platelets and endothelial cells share a common P2Y 1 receptor that mediates platelet aggregation and vasodilation. Whether P2T receptors and P2Y 1 receptors are encoded by the same gene remains to be established through knock-out experiments.
